Landmark trial
Preoperative chemoradiotherapy for esophageal or junctional cancer
van Hagen P, Hulshof MC, van Lanschot JJ, et al. · CROSS Group
DoseLab summary
Phase 3 CROSS trial: weekly carboplatin and paclitaxel with 41.4 Gy in 23 fractions before surgery improved survival over surgery alone for esophageal and junctional cancer. Citation checked against Europe PMC.
Why this is useful
The trial behind the 41.4 Gy in 23 fraction preoperative schedule with weekly carboplatin and paclitaxel.
Reference details
- Title
- Preoperative chemoradiotherapy for esophageal or junctional cancer
- Authors / organization
- van Hagen P, Hulshof MC, van Lanschot JJ, et al. · CROSS Group
- Publication / protocol
- N Engl J Med. 2012;366(22):2074–2084
- Version
- Pending verification
- Year
- 2012
- DOI
- 10.1056/NEJMoa1112088
- Disease sites
- GI
- Topics
- Esophagus, Preoperative, Landmark trial
- Fractionation context
- 41.4 Gy / 23 fx
- Last reviewed by DoseLab
- Pending verification